Stay updated on SGN-PDL1V in Advanced Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SGN-PDL1V in Advanced Solid Tumors Clinical Trial page.

Latest updates to the SGN-PDL1V in Advanced Solid Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedHepatocellular carcinoma was added to the list of conditions, and the page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check25 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

- Check39 days agoChange DetectedAdded hepatocellular carcinoma, endometrial cancer, and pancreatic adenocarcinoma as study indications; updated the study locations to 61 sites.SummaryDifference2%

- Check53 days agoChange DetectedAdded Gastric cancer as a study condition. Removed government funding lapse notice and updated page revision to v3.4.2.SummaryDifference0.3%

- Check61 days agoChange DetectedThe page now displays a government-funding lapse notice about possible delays and updates the site revision from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check68 days agoChange DetectedAdded a Show glossary option and new meta-information fields: Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Removed or replaced items include Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to SGN-PDL1V in Advanced Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SGN-PDL1V in Advanced Solid Tumors Clinical Trial page.